Insider Transactions in Q1 2024 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2024
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
109,768
+14.75%
|
$109,768
$1.57 P/Share
|
|
Mar 19
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,795
-7.05%
|
$25,590
$2.09 P/Share
|
|
Mar 19
2024
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,971
-3.35%
|
$5,942
$2.09 P/Share
|
|
Mar 19
2024
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
20,223
-3.71%
|
$40,446
$2.09 P/Share
|
|
Mar 19
2024
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
5,268
-4.28%
|
$10,536
$2.09 P/Share
|
|
Mar 19
2024
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,562
-5.63%
|
$13,124
$2.09 P/Share
|
|
Jan 18
2024
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+14.18%
|
-
|
|
Jan 18
2024
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.46%
|
-
|
|
Jan 18
2024
|
Christopher Ogden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+31.09%
|
-
|
|
Jan 18
2024
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+16.89%
|
-
|
|
Jan 18
2024
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+50.0%
|
-
|
|
Jan 18
2024
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+12.64%
|
-
|